Global Ganja Report

The Internet is atwitter over a June 19 report in the Santa Monica Observer with the headline: "US Gov't Will Legalize Marijuana on August 1." The article claims that "weed will soon be legal in all 50 states, with a prescription," thanks to the imminent government action, with cannabis about to be switched from Schedule I to Schedule II. An unnamed DEA attorney is quoted as saying: "Whatever the law may be in California, Arizona or Utah or any other State, because of Federal preemption this will have the effect of making THC products legal with a prescription, in all 50 states." The story also cites a June 17 article in the Denver Post asserting (with no attribution) that the DEA will issue a decision in the matter by July 1.

A group of 22 medical experts convened by Johns Hopkins University and The Lancet, Britain's foremost medical journal, on March 24 issued a call for the decriminalization of all non-violent drug use and possession, flatly calling the international war on drugs a failure. The paper by the Johns Hopkins-Lancet Commission on Public Health and International Drug Policy (PDF) calls on the world's governments to "move gradually toward regulated drug markets and apply the scientific method to their assessment." Dr. Chris Beyrer, a professor at Johns Hopkins Bloomberg School of Public Health and the senior author of the report, told the CBC: "We've had three decades of the war on drugs, we've had decades of zero-tolerance policy. It has had no measurable impact on supply or use, and so as a policy to control substance use it has arguably failed. It has evidently failed."

The trial of a paralyzed man who was prosecuted by Swedish authorities for self-medicating with cannabis has sparked debate over legalization in the Scandinavian nation, according to a March 27 report in Sweden's English-language The Local. Andreas Thörn, 37, who broke his neck in a motorcycle accident in 1994, used cannabis for relief from neuropathic pain as well as anxiety and depression. He was initially acquitted in August 2015 after successfully using a medical defense. Thörn said he had tried numerous pharmaceuticals which did not help, and had run out of legal options. Claes Hultling, spinal injury specialist at the Karolinska Institute, testified that studies indicate barely a fifth of spinal cord patients can be treated with the drugs available today.

There conitnues to be no end to false Internet rumors concerning our favorite herb. The most recent, currently being widely circulated on Facebook, claims that NASA-affiliated scientists at the University of Hawaii discovered "trace amounts of Tetrahydrocannabinol (THC) on a meteorite found in the Nevada desert in 2010." One of the scientists (conveniently anonymous) is quoted: "These findings will have a profound impact on the science of astrobiology as a whole. If psychoactive elements are found outside of this planet's atmosphere, what does it say about the rest of the universe? If these chemical substances, that change brain functions and result in alterations in perception, mood, or consciousness in mammals as well as humans, find their origin in outer space, what role then has cometary impacts played on the human species? Or on life on the planet as whole? This discovery ultimately leaves us with more questions than answers. It also gives a whole new meaning to the term getting high." D'oh!

There is no end to false Internet rumors concerning our favorite herb, and the latest was just called out by those dogged rumor-busters at Snopes. It seems that Britain's Sky News of Jan. 13 reported on a clinical trial of an experimental drug in France that went horribly wrong, leaving one brain-dead and another three with what could be permanent brain damage. A total of 90 were given then new painkiller compound manufactured by the Portuguese pharma firm BIAL in a test overseen by UK-based Biotrial. The original Sky News account (as quoted by Snopes) refered to the compound as "cannabis-based." Currently, it only says that French Health Minister Marisol Touraine "denied reports the drug was based on the compound found in cannabis." But it got around before the text was changed, popping up on e-mail lists and social media.

Following through on a pledge made last month, Colombian President Juan Manuel Santos on Dec. 22 signed a decree broadly legalizing medical marijuana. The new regulation—making it legal to grow, process, import and export cannabis for medical and scientific use—was hailed by Santos as positioning Colombia "at the forefront in the fight against disease." In a line clearly aimed at placating Washington, he also insisted that "the medicinal use of cannabis does not go counter to our international commitments in the field of drug control."

Philadelphia Inquirer columnist Chris Goldstein got hold of a leaked 45-page internal equity report from high-finance titan Merrill Lynch, wealth management division of Bank of America, looking at the future prospects for America's cannabis industry. Goldstein wrote it up for his occassional series Philly420 Dec. 8 under the title "Merrill Lynch is bullish on marijuana." Goldstein finds: "Carefully researched, it was an interesting peek at how heavy hitters on Wall Street are starting to view the expanding industry."

US District Judge Kimberly Mueller in Sacramento—who made history by granting the first extended hearings in federal court on the question of cannabis' continued listing under Schedule I of the Controlled Substances Act—on April 15 closed the hearings by ruling that the plant's Schedule I status is constitutional. "At some point in time," said Judge Mueller in issuing her decision in US v. Schweder et al, "a court may decide this status to be unconstitutional. But this is not the court and not the time." The Obama appointee decided to rule on the merits of the case, disregarding the insistence of federal prosecutors that she dismiss the motion for lack of standing by the defendants. For her standard of review, she applied the "rational basis test" to the defendants' challenge to cannabis' Schedule I status under the Equal Protection Clause. Under that standard, said Judge Mueller, "the statute passes muster. The questions raised by the defense are for Congress to resolve." Defendants say they will appeal to the Ninth Circuit. (The Leaf Online, Courthouse News Service, April 15)